The jury is still out on oestrogens and oestrogen/progestin and the heart [2] (multiple letters)
dc.contributor.author | Cheifitz R.L. | |
dc.contributor.author | Hough S. | |
dc.date.accessioned | 2011-05-15T15:56:43Z | |
dc.date.available | 2011-05-15T15:56:43Z | |
dc.date.issued | 2003 | |
dc.description.abstract | [No abstract available] | |
dc.description.version | Letter | |
dc.identifier.citation | Cardiovascular Journal of South Africa | |
dc.identifier.citation | 14 | |
dc.identifier.citation | 1 | |
dc.identifier.issn | 10159657 | |
dc.identifier.uri | http://hdl.handle.net/10019.1/10002 | |
dc.subject | estrogen | |
dc.subject | gestagen | |
dc.subject | raloxifene | |
dc.subject | breast cancer | |
dc.subject | cardiovascular disease | |
dc.subject | cardiovascular risk | |
dc.subject | clinical trial | |
dc.subject | controlled clinical trial | |
dc.subject | dose response | |
dc.subject | drug indication | |
dc.subject | estrogen therapy | |
dc.subject | heart protection | |
dc.subject | high risk population | |
dc.subject | hormone substitution | |
dc.subject | human | |
dc.subject | ischemic heart disease | |
dc.subject | letter | |
dc.subject | patient selection | |
dc.subject | primary prevention | |
dc.subject | randomized controlled trial | |
dc.subject | risk assessment | |
dc.subject | stroke | |
dc.subject | thromboembolism | |
dc.subject | treatment indication | |
dc.subject | treatment outcome | |
dc.subject | Coronary Disease | |
dc.subject | Estrogen Replacement Therapy | |
dc.subject | Estrogens | |
dc.subject | Female | |
dc.subject | Humans | |
dc.subject | Progestins | |
dc.subject | Risk Factors | |
dc.subject | Treatment Failure | |
dc.title | The jury is still out on oestrogens and oestrogen/progestin and the heart [2] (multiple letters) | |
dc.type | Letter |